Synthes is fighting an ex-employee in court alleging, among other things, illegal use of proprietary information. This week, he's fighting back.
Bayer failed to stop 8 women from seeking class-action status for their sex-discrimination claims against the company.
A U.S. judge sided with death row inmates who sued the FDA for importing a drug used in lethal injections. The prisoners had claimed the agency's decision to allow foreign versions of sodium thiopental into the U.S. violated its own drug-approval rules.
Two plaintiffs' lawyers experienced in pharma liability litigation have been tapped to lead the group managing thousands of suits alleging that Takeda Pharmaceutical's diabetes drug Actos caused bladder cancer, Bloomberg reports.
AstraZeneca is seeking an injunction to block Seroquel copies at least until a court can review its claims. The drugmaker says the FDA shouldn't be allowed to usher generic Seroquel onto the market until Dec. 2, when data exclusivity expires.
Litigation is testing whether manufacturing problems at a pharmaceutical plant that led to a drug shortage can be considered legal negligence--as well as whether the manufacturer can be held accountable for patients' deaths.
Tekmira Pharmaceuticals ($TKMR) fired back at Alnylam Pharmaceuticals ($ALNY) in federal court this week, with an attempt to get rid of the Massachusetts company's patent lawsuit over siRNA and lipid nanoparticle drug delivery technology.
Another batch of sales reps has sued Novo Nordisk ($NVO) for overtime. The would-be class action suit, which was filed by two reps, is seeking $70 million in overtime pay. Like so many other lawsuits--pending and otherwise--this one alleges a drugmaker misclassified its reps as exempt salaried workers when they should have been eligible for overtime.
Teva Pharamaceuticals ($TEVA) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its...
A New Jersey jury has let Johnson & Johnson's ($JNJ) Risperdal off the hook for a patient's diabetes. But the panel determined that the company didn't do enough to warn the man's...